Russian Health Minister Mikhail Murashko has revealed the allocation of 51 billion rubles as part of national initiatives aimed at tackling oncological diseases, alongside extensive plans to upgrade the medical infrastructure. During his speech at the “National Healthcare” congress, he reported that Russian scientists are currently conducting clinical trials of domestic drugs based on oncologic viruses to combat oncological diseases, completing preclinical trials of a drug for Crigler-Najjar syndrome and preparing to conduct a clinical trial. Murashko highlighted the strategic priorities for advancing Russian healthcare, emphasizing the critical importance of import substitution and the integration of domestic innovations.
The Minister paid great attention to the achievements of the Russian pharmaceutical industry. He recalled that today more than 70% of the domestic pharmaceutical market consists of Russian drugs. “Our task is not only to support the production of vital drugs, but also to develop new, breakthrough treatment methods,” Murashko emphasized. At the same time, according to him, domestic products already account for 42% of the medical products market (thanks to national projects).
Mikhail Murashko also spoke about the importance of supporting new Russian developments in pharmaceuticals, such as gene therapy drugs for the treatment of rare diseases, including spinal muscular atrophy and hemophilia.
